Olmesartan Glenmark (Olmesartan Medoxomil)

Olmesartan medoxil is an antihypertensive agent that works within the renin‑angiotensin‑aldosterone system to lower blood pressure.

• Essential hypertension: helps achieve target blood pressure and reduce cardiovascular risk.
• Diastolic hypertension: provides effective reduction of diastolic pressure when systolic control is adequate.
• Hypertension with chronic kidney disease: assists in slowing progression of renal impairment by lowering systemic pressure.

• Olmesartan medoxil selectively blocks the binding of angiotensin II to the AT1 receptors on vascular smooth‑muscle and adrenal cells. This inhibition prevents vasoconstriction and aldosterone secretion, leading to relaxation of blood vessels, reduced peripheral resistance, and ultimately a decrease in arterial blood pressure.

Olmesartan medoxil may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects

• Dizziness or light‑headedness
• Headache
• Fatigue
• Nasal congestion
• Diarrhoea
• Cough

Serious or Rare Side Effects

• Angio‑edema involving the face, lips or tongue
• Severe hypotension
• Acute kidney injury
• Hyperkalemia
• Liver enzyme elevations
• Allergic skin reactions such as Stevens‑Johnson syndrome

When using Olmesartan medoxil, certain precautions should be observed to ensure safety and effectiveness.

• Monitor blood pressure: check regularly to confirm therapeutic response.
• Assess renal function: evaluate kidney parameters before initiation and periodically thereafter.
• Check electrolytes: especially potassium levels, to avoid hyperkalaemia.
• Avoid use in pregnancy: drug is contraindicated in the second and third trimesters.
• Review concomitant medications: assess for potential additive blood‑pressure‑lowering effects.
• Store below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Olmesartan medoxil can interact with several medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Combined use with aliskiren in diabetic patients: risk of renal impairment and hyperkalaemia.
• Concomitant use with potassium‑saving diuretics or supplements: may cause dangerous hyperkalaemia.

Moderate Interactions (Monitor Closely)

• Non‑steroidal anti‑inflammatory drugs (NSAIDs): can blunt antihypertensive effect and affect renal function.
• Lithium: may increase lithium levels, risking toxicity.
• Dual renin‑angiotensin system blockade (e.g., ACE inhibitor): heightens risk of hypotension, renal dysfunction, and hyperkalaemia.